Table 4.
Best Anti-Tumor Response According to the mRECIST
| Lenvatinib Group (n=27) | Lenvatinib Plus Camrelizumab Group(n=21) | |
|---|---|---|
| Complete response | 0 (0%) | 0 (0%) |
| Partial response | 2 (7.41%) | 6 (28.57%) |
| Stable disease | 12 (44.44%) | 9 (42.86%) |
| Progressive disease | 13 (38.15%) | 6 (28.57%) |
| Objective Response Rate | 7.41% | 28.57% |
| Disease Control Rate | 51.85% | 71.43% |
Note: Responses were evaluated according to modified Response Evaluation Criteria in Solid Tumors version by investigators.